BioTuesdays

Category - Markets

AcelRx Pharma Logo
Markets

Ladenburg starts AcelRx Pharma at buy; PT $7

Ladenburg Thalmann launched coverage of AcelRx Pharmaceuticals (NASDAQ:ACRX) with a “buy” rating and price target of $7. The stock closed at $2.95 on August 15. AcelRx is focused on the development of acute pain...

August 16, 2018
Cytori Logo
Markets

Maxim cuts Cytori Therapeutics to hold, removes PT

Maxim Group downgraded Cytori Therapeutics (NASDAQ:CYTX) to “hold” from “buy” and removed its price target, citing capital concerns. The stock closed at 40 cents on August 14. “Our fundamental view around the...

August 15, 2018
ObsEva Logo
Markets

Leerink resumes coverage of ObsEva at OP; PT $25

Leerink resumed coverage of ObsEva SA (NASDAQ:OBSV) with an “outperform” rating and $25 price target. The stock finished at $13 on August 14. “We believe that at current levels the stock does not fully reflect the...

August 15, 2018
Dicerna Logo
Markets

HCW ups Dicerna Pharma to buy; PT $21

H.C. Wainwright upgraded Dicerna Pharmaceuticals (NASDAQ:DRNA) to “buy” from “neutral” and raised its price target to $21 from $14, citing broad progress across the company’s pipeline. The stock closed at $14.82 on...

August 15, 2018
Idera Pharma Logo
Markets

JP Morgan ups Idera Pharma to OW; PT $15

JP Morgan upgraded Idera Pharmaceuticals (NASDAQ:IDRA) to “overweight” with a December 2019 price target of $15, following a period of restriction and a “not-rated” designation. JP Morgan had rated the stock, which...

August 15, 2018
Replimune Group Logo
Markets

Analysts start Replimune at OP and OW; PTs $25, $26

Analysts for Leerink and JP Morgan initiated coverage for Replimune (NASDAQ:REPL) with “outperform” and “overweight” ratings, respectively. Leerink set its price target at $25 and JP Morgan at $26 for December 2019...

August 14, 2018
Correvio Pharma Logo
Markets

Mackie cuts Correvio Pharma to hold but ups PT to $4.70

Mackie Research downgraded Correvio Pharma (NASDAQ:CORV) to “hold” from “speculative buy” but raised its price target to $4.70 from $3.30, citing the stock’s run up after a positive FDA announcement on the company’s...

August 13, 2018
Gemphire Logo
Markets

Roth cuts Gemphire Therapeutics to neutral; PT $2

Roth Capital Partners downgraded Gemphire Therapeutics (NASDAQ:GEMP) to “neutral” from “buy” with a $2 price target after the company terminated its Phase 2a pediatric non-alcoholic fatty liver disease (NAFLD) trial...

August 13, 2018
Scynexis Logo
Markets

Ladenburg cuts Scynexis PT to $6 from $10

Ladenburg Thalmann lowered its price target for Scynexis (NASDAQ:SCNX) to $6 from $10, citing another delay in development of an IV formulation of ibrexafungerp. The stock closed at $1.39 on August 10. “As successful as...

August 13, 2018